IL314504A - Abexitide for the treatment of hyperinsulinemic hypoglycemia - Google Patents
Abexitide for the treatment of hyperinsulinemic hypoglycemiaInfo
- Publication number
- IL314504A IL314504A IL314504A IL31450424A IL314504A IL 314504 A IL314504 A IL 314504A IL 314504 A IL314504 A IL 314504A IL 31450424 A IL31450424 A IL 31450424A IL 314504 A IL314504 A IL 314504A
- Authority
- IL
- Israel
- Prior art keywords
- formulation
- administered
- subject
- buffered liquid
- hypoglycemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745915P | 2018-10-15 | 2018-10-15 | |
| US201862746229P | 2018-10-16 | 2018-10-16 | |
| US201962823493P | 2019-03-25 | 2019-03-25 | |
| PCT/US2019/056278 WO2020081534A1 (en) | 2018-10-15 | 2019-10-15 | Avexitide for the treatment of hyperinsulinemic hypoglycemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314504A true IL314504A (en) | 2024-09-01 |
Family
ID=70283142
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314504A IL314504A (en) | 2018-10-15 | 2019-10-15 | Abexitide for the treatment of hyperinsulinemic hypoglycemia |
| IL282059A IL282059A (en) | 2018-10-15 | 2021-04-05 | Abexitide for the treatment of hyperinsulinemic hypoglycemia |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL282059A IL282059A (en) | 2018-10-15 | 2021-04-05 | Abexitide for the treatment of hyperinsulinemic hypoglycemia |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210338780A1 (enExample) |
| EP (2) | EP3867266A4 (enExample) |
| JP (2) | JP2022513351A (enExample) |
| CN (1) | CN112867730A (enExample) |
| AU (2) | AU2019359807B2 (enExample) |
| BR (1) | BR112021006968A2 (enExample) |
| CA (1) | CA3115527A1 (enExample) |
| CL (1) | CL2021000892A1 (enExample) |
| IL (2) | IL314504A (enExample) |
| WO (1) | WO2020081534A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3115527A1 (en) * | 2018-10-15 | 2020-04-23 | Eiger Biopharmaceuticals, Inc. | Avexitide for the treatment of hyperinsulinemic hypoglycemia |
| US20240307501A1 (en) | 2021-06-21 | 2024-09-19 | Eiger Biopharmaceuticals, Inc. | Treatment of congenital hyperinsulinism with avexitide |
| WO2024220962A1 (en) * | 2023-04-21 | 2024-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Glp-1r antagonism to improve nutrition following gastrointestinal surgery |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| WO2013120022A2 (en) * | 2012-02-08 | 2013-08-15 | Seneb Biosciences, Inc. | Treatment of hypoglycemia |
| WO2015022420A1 (en) * | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| SMT202100668T1 (it) * | 2015-05-22 | 2022-01-10 | Univ Leland Stanford Junior | Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1 |
| US10653753B2 (en) * | 2016-03-04 | 2020-05-19 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
| JP7584894B2 (ja) * | 2016-11-21 | 2024-11-18 | アイガー・バイオファーマシューティカルズ・インコーポレイテッド | エキセンディン（９－３９）の緩衝製剤 |
| CA3115527A1 (en) * | 2018-10-15 | 2020-04-23 | Eiger Biopharmaceuticals, Inc. | Avexitide for the treatment of hyperinsulinemic hypoglycemia |
-
2019
- 2019-10-15 CA CA3115527A patent/CA3115527A1/en active Pending
- 2019-10-15 US US17/285,039 patent/US20210338780A1/en active Pending
- 2019-10-15 WO PCT/US2019/056278 patent/WO2020081534A1/en not_active Ceased
- 2019-10-15 CN CN201980068180.8A patent/CN112867730A/zh active Pending
- 2019-10-15 IL IL314504A patent/IL314504A/en unknown
- 2019-10-15 EP EP19873113.5A patent/EP3867266A4/en not_active Withdrawn
- 2019-10-15 BR BR112021006968-2A patent/BR112021006968A2/pt unknown
- 2019-10-15 EP EP23151717.8A patent/EP4233842A3/en active Pending
- 2019-10-15 JP JP2021545283A patent/JP2022513351A/ja active Pending
- 2019-10-15 AU AU2019359807A patent/AU2019359807B2/en active Active
-
2021
- 2021-04-05 IL IL282059A patent/IL282059A/en unknown
- 2021-04-12 CL CL2021000892A patent/CL2021000892A1/es unknown
-
2024
- 2024-09-27 JP JP2024168092A patent/JP2025000798A/ja active Pending
-
2025
- 2025-07-23 AU AU2025208421A patent/AU2025208421A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019359807A1 (en) | 2021-05-13 |
| EP4233842A2 (en) | 2023-08-30 |
| WO2020081534A1 (en) | 2020-04-23 |
| AU2025208421A1 (en) | 2025-08-14 |
| CN112867730A (zh) | 2021-05-28 |
| US20210338780A1 (en) | 2021-11-04 |
| CA3115527A1 (en) | 2020-04-23 |
| EP4233842A3 (en) | 2023-10-25 |
| EP3867266A1 (en) | 2021-08-25 |
| AU2019359807B2 (en) | 2025-04-24 |
| JP2025000798A (ja) | 2025-01-07 |
| IL282059A (en) | 2021-05-31 |
| BR112021006968A2 (pt) | 2021-07-27 |
| JP2022513351A (ja) | 2022-02-07 |
| CL2021000892A1 (es) | 2021-11-12 |
| EP3867266A4 (en) | 2022-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goldenberg et al. | Semaglutide: review and place in therapy for adults with type 2 diabetes | |
| Craig et al. | Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia | |
| Umpierrez et al. | Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) | |
| Clancy et al. | Post− gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia | |
| Sakai et al. | Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials | |
| WO2024129676A1 (en) | Dosage regime of orforglipron for treating a subject with type 2 diabetes (t2d), obesity, or overweight with at least one weight related comorbidity | |
| IL307966A (en) | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug | |
| Crepaldi et al. | Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management | |
| Goldenberg et al. | Managing the course of kidney disease in adults with type 2 diabetes: from the old to the new | |
| Holzäpfel et al. | Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration | |
| JP2025000798A (ja) | 高インシュリン血症性低血糖症の治療のためのアベキシド | |
| Cariou et al. | Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series | |
| JP2022513351A5 (enExample) | ||
| Perin et al. | New oral antidiabetic agents | |
| Boehm et al. | Use of somatostatin receptor ligands in obesity and diabetic complications | |
| Eid | Obesity and type 2 diabetes mellitus in South Dakota: focused insight into prevalence, physiology and treatment. | |
| Engel et al. | Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin | |
| Lebovitz | Hyperglycemia secondary to nondiabetic conditions and therapies | |
| Aijazi et al. | Exenatide induced acute kidney injury | |
| Arevalo et al. | 6567 Novel Indication of GLP-1 Receptor Agonists Beyond Weight Loss: Addressing Post-Gastric Bypass Late Dumping Syndrome | |
| Kang et al. | Effectiveness and safety of adding basal insulin glargine in patients with type 2 diabetes mellitus exhibiting inadequate response to metformin and dpp-4 inhibitors with or without sulfonylurea | |
| Meier et al. | Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment | |
| Horowitz et al. | DPP-4 inhibition and the known unknown | |
| El Hefnawy et al. | Safety and efficacy of SGLT2 inhibitors versus DPP4 inhibitors in fasting patients with T2-diabetes mellitus during ramadan in Egypt (EMPA-Ramadan) | |
| Goodchild et al. | Managing diabetes in the presence of renal impairment |